Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

Inclusion Criteria: * Type II diabetes mellitus * Subjects who have not been taking any oral hypoglycemic agent within 8 weeks from screening or who have been taking metformin monotherapy at the same dose for more than 8 weeks before screening * Subjects with 6.5%≤HbA1c≤9.0% at screening * Subjects with 20kg/m2≤BMI≤40kg/m2 at screening Exclusion Criteria: * Type I diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus * AST \> upper normal range\*3 * Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption * Subjects who experienced hypersensitivity reaction against DPP-4 inhibitors, thiazolidinediones * Pregnant women